Pembrolizumab Disease-Free Survival Persists Long Term in RCC
Updated data from the KEYNOTE-564 trial shows pembrolizumab disease-free survival persists long...
Read More
Dissemination (Meeting Coverage)
Good Response With Nivolumab Plus Axitinib in Metastatic RCC
Combination treatment with nivolumab plus axitinib has achieved a high response rate in...
Read More
Biomarkers Predict Response to Immune Nivolumab (± Ipilimumab) in Advanced RCC
Biomarker analysis of the phase 2 TITAN-RCC trial identified specific immune cell-related...
Read More
Avelumab Plus Axitinib May Benefit High-Risk Early RCC
Results of the NeoAvAx trial indicate that the neoadjuvant combination of avelumab plus axitinib...
Read MoreHealth and Safety at ASCO GU 2022
Individual Accountability ASCO is committed to maintaining the health and safety of all ASCO Genitourinary Cancers Symposium attendees. We will be reviewing the latest Centers for Disease Control and Prevention and World Health...
Read MoreActive Surveillance Helps Delay Systemic Therapy in Some With Metastatic Renal Cell Carcinoma
Active surveillance (AS) may be used effectively in a subgroup of patients(pts) with metastatic renal cell carcinoma (RCC) and indolent disease to postpone the commencement of systemic treatment without affecting long-term...
Read MoreMindfulness App Helps Address Psychosocial Distress in Patients With Metastatic Renal Cell Carcinoma
mRCC was linked to a high incidence of distress, a high degree of symptom load, and a wide range of quality-of-life impairments. A smartphone application aimed at enhancing mindfulness has been developed from a Mindfulness-Based...
Read MoreTele-mentoring Benefits Patients With Renal Cell Carcinoma
In recent years, the overall survival from metastatic renal cell carcinoma (RCC) has improved, mainly in part due to immune checkpoint inhibitors (ICI) and tyrosine kinase inhibitors (TKI). TKI and ICI had distinct and...
Read MoreResponse to Lenvatinib + Pembrolizumab in Advanced Renal Cell Carcinoma Regardless of Biomarker Status
Lenvatinib (lenva) + pembrolizumab (pembro) demonstrated encouraging antitumor activity and controllable safety characteristics in treatment-naive (n=23) or earlier cured metastatic RCC (n=105, initially medicated with immune...
Read MoreASCO GU Program Guide 2022
Thursday, Feb 17: Exhibits Open 10:00 AM – 9:45 PM EST Novel Treatment Implementation: Prostate-Specific Membrane Antigen Targeting and Beyond Primary Track: Prostate Cancer 10:45 AM – 12:30 PM EST Optimizing Management of...
Read MoreASCO GU 2022 Is Here!
Program at a Glance • Highly interactive sessions with multidisciplinary perspectives on new, innovative findings in the study, diagnosis, and treatment of GU malignancies. • Presentation of the latest novel science and...
Read More
Precision Medicine: It’s All About Biomarker Testing
Guidelines recommend biomarker testing, but is it done? Next-generation sequencing (NGS) may help...
Read More
ESC: Finerenone Demonstrates CVD Benefit in FIGARO-DKD
Benefit driven by 29% relative reduction in heart failure hospitalization SGLT2 inhibitors were...
Read MorePhase 3 GLOW: first-line ibrutinib plus venetoclax improves outcomes in elderly or unfit CLL
With an updated median follow-up of 34.1 months, the 30-month progression-free survival (PFS) was 80.5% with ibrutinib plus venetoclax versus 35.8% for chlorambucil plus obinutuzumab in elderly or unfit patients with chronic...
Read MoreReduced risk of Alzheimer’s disease in CHIP carriers
Clonal hematopoiesis of indeterminate potential (CHIP) was related to decreased risk of Alzheimer’s disease (AD) and AD neuropathological changes. Mutated hematopoietic stem cells were detected in the brains of CHIP carriers....
Read MoreUKALL 2003: therapy de-escalation safe in low-risk MRD patients with ALL
Therapy de-escalation in patients with acute lymphoblastic leukemia (ALL) and a low-risk minimal residual disease (MRD) profile was safe, 10-year follow-up results of the UKALL 2003 trial show. Patients with a high-risk MRD...
Read MoreHeavily pre-treated FLT3-mutated AML population may benefit from novel triplet regimen
A combination treatment of quizartinib plus venetoclax plus decitabine was highly active in patients with relapsed/refractory FLT3-ITD-mutated acute myeloid leukemia (AML). Patients with RAS/MAPK and FLT3-F691L mutations...
Read MoreEncouraging results of novel triplet combination for AML
A regimen of cladribine plus low-dose cytarabine plus venetoclax alternated with 5-azacytidine plus venetoclax showed encouraging efficacy in patients with newly diagnosed acute myeloid leukemia (AML). Moreover, the displayed...
Read MorePromising frontline triplet regimen for TP53-mutated AML
A triplet combination of 5-azacitidine, venetoclax, and magrolimab displayed promising response rates in newly diagnosed older, unfit, or TP53-mutated patients with acute myeloid leukemia (AML). Moreover, the phase 1b/2 study...
Read MoreATLAS-INH: impressive results of fitusiran for hemophilia
Treatment with fitusiran prophylaxis led to a lower rate of bleeding events and an improved health-related quality of life in patients with hemophilia A or B with inhibitors. The observed safety profile of fitusiran in phase 3...
Read More